API reference
Gadoteridol
- CAS number
- 120066-54-8
- Molecular formula
- C17H29GdN4O7
- Molecular weight
- 558.7 g/mol
About this molecule
Gadoteridol is a macrocyclic nonionic gadolinium that provides contrast enhancement of the brain, spine, and surrounding tissues, resulting in improved visualization (compared with unenhanced MRI) of lesions with abnormal vascularity or those thought to disrupt the normal blood-brain barrier. It was 1 of the 3 macrocyclic gadolinium-based contrast agents (GBCAs) that was mandated by the EMA to replace linear gadolinium-based contrast agents due to concerns about retained gadolinium in the brain. Initially approved by the FDA in 1992, gadoteridol received additional approval in 2020 for use in pediatric patients less than 2 years old.
Source: DrugBank, via PubChem.
Identifiers
- IUPAC name
- 2-[4,7-bis(carboxylatomethyl)-10-(2-hydroxypropyl)-1,4,7,10-tetrazacyclododec-1-yl]acetate;gadolinium(3+)
- InChIKey
- DPNNNPAKRZOSMO-UHFFFAOYSA-K
- SMILES
- CC(CN1CCN(CCN(CCN(CC1)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])O.[Gd+3]
- PubChem CID
- 60714
Also known as
ProHance · Gadolinium-HP-DO3A · Prohance Multipack · GD-HP-DO 3A · Gd-HPDO3A · Gd-HP-DO3A · Gadolinium-HP-Do 3A · SQ 32,692
Chemical data on this page is drawn from PubChem (National Library of Medicine) and is provided for identification only. Hanpars does not hold stock of every substance listed; availability, grade, documentation and regulatory status are confirmed per enquiry.
Tell us the grade, the quantity and the market.
Send the molecule or ingredient, the specification and the destination. We reply from Tehran with the questions, the documents and the next step.